• Lavoie SmithEllen MEMSchool of Nursing, University of Michigan, Ann Arbor, MI, USA., Lang Li, ChienWei Chiang, Karin Thomas, Raymond J Hutchinson, Elizabeth M Wells, Richard H Ho, Jodi Skiles, Arindom Chakraborty, Celia M Bridges, and Jamie Renbarger.
• School of Nursing, University of Michigan, Ann Arbor, MI, USA.
• J. Peripher. Nerv. Syst. 2015 Mar 1; 20 (1): 37-46.

AbstractVincristine, a critical component of combination chemotherapy treatment for pediatric acute lymphoblastic leukemia (ALL), can lead to vincristine-induced peripheral neuropathy (VIPN). Longitudinal VIPN assessments were obtained over 12 months from newly diagnosed children with ALL (N = 128) aged 1-18 years who received vincristine at one of four academic children's hospitals. VIPN assessments were obtained using the Total Neuropathy Score-Pediatric Vincristine (TNS©-PV), National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE©), Balis© grading scale, and Pediatric Neuropathic Pain Scale©-Five (PNPS©-5). Of children who provided a full TNS©-PV score, 85/109 (78%) developed VIPN (TNS©-PV ≥4). Mean TNS©-PV, grading scale, and pain scores were low. CTCAE©-derived grades 3 and 4 sensory and motor VIPN occurred in 1.6%/0%, and 1.9%/0% of subjects, respectively. VIPN did not resolve in months 8-12 despite decreasing dose density. VIPN was worse in older children. Partition cluster analysis revealed 2-3 patient clusters; one cluster (n = 14) experienced severe VIPN. In this population, VIPN occurs more commonly than previous research suggests, persists throughout the first year of treatment, and can be severe. © 2015 Peripheral Nerve Society.

22 keywords...

hide…